Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Petros Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/15/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment to the Amended and Restated By-laws of Petros Pharmaceuticals, Inc."
07/13/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "CERTIFICATE OF DESIGNATIONS OF CONVERTIBLE PREFERRED STOCK OF",
"Form of Warrant Neither the issuance and sale of the securities represented by this certificate nor the securities into which these securities are exercisable have been registered under the securities act of 1933, as amended, or applicable state securities laws. The securities may not be offered for sale, sold, transferred or assigned in the absence of an effective registration statement for the securities under the securities act of 1933, as amended, or an opinion of counsel to the holder , in a form reasonably acceptable to the company, that registration is not required under said act or unless sold or eligible to be sold pursuant to rule 144 or rule 144a under said act. Notwithstanding the foregoing, the securities may be pledged in connection with a bona fide margin account or other lo...",
"RECITALS",
"Registration Rights Agreement",
"Petros Pharmaceuticals Announces Capital Raise of $15 million"
11/30/2022 8-K Quarterly results
11/15/2022 8-K Quarterly results
Docs: "Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update"
08/15/2022 8-K Quarterly results
Docs: "Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022"
07/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Petros Pharmaceuticals Responds to Fraudulent Press Release"
06/24/2022 8-K Quarterly results
04/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology"
04/04/2022 8-K Quarterly results
Docs: "Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights"
04/01/2022 8-K/A Quarterly results
03/04/2022 8-K Quarterly results
01/24/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
01/21/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "PLEASE NOTE: CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SETTLEMENT AGREEMENT This SETTLEMENT AGREEMENT, dated as of January 18, 2022, is entered into by and between METUCHEN PHARMACEUTICALS LLC, a Delaware limited liability company and VIVUS LLC, a Delaware limited liability company and formerly VIVUS, Inc. . Metuchen and VIVUS are collectively referred to as the “ Parties ” and each a “ Party .” WHEREAS, Metuchen and VIVUS are parties to that certain License and Commercialization Agreement, dated September 30, 2016 , pursuant to which VIVUS granted to Metuchen an exclusive license in the Territory for, among other things, the development and commercialization of the therapeuti...",
"PROMISSORY NOTE",
"Security Agreement, between Metuchen Pharmaceuticals LLC and VIVUS LLC, a Delaware limited liability company",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
12/27/2021 8-K Quarterly results
12/23/2021 8-K Quarterly results
12/01/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "COMMON STOCK PURCHASE WARRANT PETROS PHARMACEUTICALS, INC. Warrant Shares: _______ Initial Exercise Date: December [•], 2021 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on [•], [•] [1] but not thereafter, to subscribe for and purchase from Petros Pharmaceuticals, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .           Definitions . C...",
"Petros Pharmaceuticals, Inc. 1185 Avenue of the Americas, 3rd Floor New York, New York 10036",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November 29, 2021, between Petros Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended as to the Registered Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Unregistered Shares and Warrants , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully de...",
"Petros Pharmaceuticals Announces $10 Million Offering Investors included the company's largest shareholder NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. , a leading provider of therapeutics for men's health, today announces that it has entered into definitive agreements with the company's largest investor and other existing investors, for the purchase and sale of 3,333,333 shares of Petros Pharmaceuticals' common stock, at a purchase price of $3.00 per share. The company will sell 2,153,333 shares in a registered direct offering and the remaining 1,180,000 shares will be sold in a private placement. Petros Pharmaceuticals has also agreed to issue the investors unregistered warrants to acquire 2,500,000 shares of common stock at an exercise price of $3.50 per share, e..."
11/17/2021 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
10/15/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
02/25/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Re: Employment Offer Letter",
"PETROS PHARMACEUTICALS, INC. 2020 OMNIBUS INCENTIVE COMPENSATION PLAN NONQUALIFIED STOCK OPTION GRANT AGREEMENT This Nonqualified Stock Option Grant Agreement , dated as of [___], [__] , is delivered by Petros Pharmaceuticals, Inc. to [____] . RECITALS A. The 2020 Omnibus Incentive Compensation Plan provides for the grant of stock options to purchase shares of Common Stock of the Company . The Board of Directors of the Company has decided to make this nonqualified stock option grant as an inducement for the Grantee to promote the best interests of the Company and its stockholders. All capitalized terms used but not defined herein shall have the meanings ascribed to them in the Plan. A copy of the Plan is attached as Exhibit A. B. The Board is authorized to appoint a committee to administer..."
01/25/2021 8-K Quarterly results
01/19/2021 8-K Quarterly results
12/31/2020 8-K/A Quarterly results
12/15/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "†"
12/10/2020 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
12/02/2020 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modifications to Rig...
Docs: "Amended and Restated Certificate of Incorporation of Petros Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Petros Pharmaceuticals, Inc",
"Registration Rights Agreement, by and among Petros Pharmaceuticals, Inc. and JCP III SM AIV, L.P",
"Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy